drugset / Trial / NCT07392034

Efficacy of Tranexamic Acid Reducing Blood Loss During Maxillofacial Trauma Surgery

NCT07392034

Phase 2 Completed 60 enrolled Nishtar Medical University
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Tranexamic acid (TXA) is an inexpensive, easily used and relatively safe drug. It inhibits plasminogen activation and plasmin thus retards clot disintegration.Therapeutic application of tranexamic acid in trauma for preventing blood loss has been documented since long. Since blood loss causes several serious complications, it is compensated emergently by transfusion of blood or its products. However, transfusion of blood and products always carries a risk of inadvertent transmission of infection, antigen-antibody reactions and additional cost all of which can be prevented if blood loss is reduced. Morbidity associated with the delay in compensating the blood loss could also be prevented by pharmaceutically preventing hemorrhage.

Timeline

Start
2025-01-01
Primary completion
2025-06-30
Completion
2025-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 20 mg/kg Intravenous

Indications

No indication recorded.